PET for prostate cancer imaging: Still a quandary or the ultimate solution?

Journal of Nuclear Medicine

Volumn 43, Issue 2, 2002, Pages 200-202

  Kotzerke, Jörg ^a   Gschwend, Jürgen E ^a   Neumaier, Bernd ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID C 11; ANTINEOPLASTIC AGENT; CARBON 11; CHOLINE; FLUORODEOXYGLUCOSE F 18; PROSTATE SPECIFIC ANTIGEN; TOLUENESULFONIC ACID DERIVATIVE;

APOPTOSIS; BONE METASTASIS; BONE SCINTISCANNING; CANCER RECURRENCE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG TUMOR LEVEL; LAPAROSCOPIC SURGERY; LYMPH NODE METASTASIS; MALIGNANT TRANSFORMATION; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATECTOMY; SENSITIVITY AND SPECIFICITY;

CARBON RADIOISOTOPES; CHOLINE; FLUORINE RADIOISOTOPES; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036174494     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (32)

1. Combating prostate cancer
2. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate
3. Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors
4. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer
5. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy
6. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer
7. Irradiation for locally recurrent carcinoma of the prostate following radical prostatectomy
8. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose
9. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organconfined prostate cancer
10. Positron emission tomography with 18fluorine-labelled deoxyglucose: Utility in localized and advanced prostate cancer
11. Metastatic prostate cancer: Initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose
12. Detection of bony metastases of androgen-independent prostate cancer by PET-FDG
13. Phosphorylcholine: A novel second messenger essential for mitogenic activity of growth factors
14. Choline phospholipids: Signal transduction and carcinogenesis
15. Prostate cancer: Metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging
16. 1H MRS choline: Correlation with in vitro chemistry/ histology
17. PET imaging of prostate cancer using carbon-11-choline
18. Experience with carbon-11 choline positron emission tomography in prostate carcinoma
19. 11C]choline
20. Positron emission tomography of esophageal carcinoma using (11)C-choline and (18)F-fluorodeoxyglucose: A novel method of preoperative lymph node staging
21. 11C-choline PET
22. 11C]choline: Implications for in vivo imaging with positron emission tomography
23. 11C]choline: A positron-emitting tracer for tumor imaging
24. Automated synthesis of fluorine-18 labeled choline analogue: 2-Fluoroethyl-dimethyl-2-oxyethylammonium
25. 18F fluoroethylcholine for cancer imaging with PET: Synthesis, biochemistry, and prostate cancer imaging
26. 18F-labeled choline as an oncologic tracer for positron emission tomography: Initial findings in prostate cancer
27. 18F]bromofluoromethane at high specific radioactivity
28. 18F]fluoromethyl iodide: A synthetic precursor for fluoromethylation of radiopharmaceuticals
29. Substrate specificity of choline kinase
30. Nuclear medicine tomography: Systems and devices
31. Non-oxidative metabolism of C-11-acetate: New insight for lipid synthesis imaging in tumors
32. 11C-Acetate positron emission tomography (PET) of prostate cancer: First clinical experience